Literature DB >> 12773052

Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.

Romano Silvestri1, Gabriella De Martino, Giuseppe La Regina, Marino Artico, Silvio Massa, Laura Vargiu, Massimo Mura, Anna Giulia Loi, Tiziana Marceddu, Paolo La Colla.   

Abstract

The potent anti-HIV-1 activities of L-737,126 (2) and PAS sulfones prompted us to design and test against HIV-1 in acutely infected MT-4 cells a number of novel 1- and 3-benzenesulfonylindoles. Indoles belonging to the 1-benzenesulfonyl series were found poorly or totally inactive. On the contrary, some of the 3-benzenesulfonyl derivatives turned out to be as potent as 2, being endowed with potencies in the low nanomolar concentration range. In particular, (2-methylphenyl)sulfonyl (72) and (3-methylphenyl)sulfonyl (73) derivatives showed EC(50) values of 1 nM. Introduction of two methyl groups at positions 3 and 5 of the phenyl ring of 2 furnished derivatives (80 and 83) which showed very potent and selective anti-HIV-1 activity not only against the wt strain, but also against mutants carrying NNRTI-resistant mutations at positions 103 and 181 of the reverse transcriptase gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773052     DOI: 10.1021/jm0211063

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Mohammad Hassam; Adriaan E Basson; Dennis C Liotta; Lynn Morris; Willem A L van Otterlo; Stephen C Pelly
Journal:  ACS Med Chem Lett       Date:  2012-05-02       Impact factor: 4.345

3.  Dual vicinal functionalisation of heterocycles via an interrupted Pummerer coupling/[3,3]-sigmatropic rearrangement cascade.

Authors:  Mindaugas Šiaučiulis; Selma Sapmaz; Alexander P Pulis; David J Procter
Journal:  Chem Sci       Date:  2017-11-17       Impact factor: 9.825

Review 4.  N-Pyrrylarylsulfones with High Therapeutic Potential.

Authors:  Valeria Famiglini; Sabrina Castellano; Romano Silvestri
Journal:  Molecules       Date:  2017-03-09       Impact factor: 4.411

5.  Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents.

Authors:  Ming-Xia Song; Song-Hui Li; Jiao-Yang Peng; Ting-Ting Guo; Wen-Hui Xu; Shao-Feng Xiong; Xian-Qing Deng
Journal:  Molecules       Date:  2017-06-14       Impact factor: 4.411

6.  Palladium(II)-Catalyzed Synthesis of Sulfinates from Boronic Acids and DABSO: A Redox-Neutral, Phosphine-Free Transformation.

Authors:  Alex S Deeming; Claire J Russell; Michael C Willis
Journal:  Angew Chem Int Ed Engl       Date:  2015-11-24       Impact factor: 15.336

Review 7.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

8.  Cross-Coupling of Sodium Sulfinates with Aryl, Heteroaryl, and Vinyl Halides by Nickel/Photoredox Dual Catalysis.

Authors:  Huifeng Yue; Chen Zhu; Magnus Rueping
Journal:  Angew Chem Int Ed Engl       Date:  2018-01-05       Impact factor: 15.336

Review 9.  Synthetic strategies, SAR studies, and computer modeling of indole 2 and 3-carboxamides as the strong enzyme inhibitors: a review.

Authors:  Gholamabbas Chehardoli; Asrin Bahmani
Journal:  Mol Divers       Date:  2020-05-12       Impact factor: 2.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.